TESTS BEFORE
GENE THERAPY
Nobody tells you about the weeks of testing before gene therapy starts. Each test answers a specific clinical question — whether the treatment is safe to give, whether the manufactured cells will work, whether your body can handle what comes next. Here is what's being checked and why.
What This Means for Patients
The pre-treatment workup isn't the team being cautious for the sake of it. Every test answers a real clinical question — one that determines whether treatment is safe to give, whether the manufactured product will work as intended, and whether your body can handle what gene therapy involves. Conditioning chemotherapy is hard on the body. Cytokine release syndrome can stress the heart and kidneys. Manufacturing requires enough of the right cells to begin with. Testing establishes all of this before anything irreversible starts.
Key Pre-Treatment Tests and What Each Determines
Seven tests that consistently appear across gene therapy workups — each answering a specific clinical question.
| Test | What It Checks | Why It Matters |
|---|---|---|
| Genomic / Molecular Profiling of Tumor | Target antigen expression (CD19, BCMA, GD2), driver mutations, actionable features | Most critical test — confirms your tumor carries what the therapy targets. CAR-T targeting CD19 is useless without CD19 expression. |
| CBC + Metabolic Panel | Bone marrow function, kidney, liver, electrolytes | Establishes organ baseline before conditioning chemotherapy and immune activation. Borderline values get flagged and managed. |
| Cardiac Evaluation (Echocardiogram) | Left ventricular function, cardiac output | CRS drops blood pressure and stresses cardiac output. Where cardiac function stands before treatment determines management threshold after. |
| Imaging (CT/PET-CT/MRI) | Disease extent, tumor burden | Establishes disease extent going in. Some programs have disease burden limits — imaging tells you whether you're within them. |
| Infectious Disease Screening | HIV, Hepatitis B/C, CMV serostatus | CMV status affects post-infusion T-cell behavior and can influence manufacturing decisions. Not administrative — clinically informative. |
| Cell Count for Leukapheresis | CD3+ T-cell count, lymphocyte subset levels | For programs collecting your own cells — must be enough of the right cells to collect. Some patients need growth factor before collection day. |
| Performance Status Assessment | ECOG / Karnofsky functional capacity | Most programs require ECOG 0–2. Physical function affects tolerability of conditioning, manufacturing wait, and post-infusion recovery more than almost any other variable. |
Who This Is Relevant For
Any patient entering any gene therapy program. The specific tests differ by protocol — what doesn't differ is that the workup exists, takes time, and its results determine whether and when you move forward.
Benefits and Limitations
Benefits
- Catches fixable problems earlyBorderline kidney function found now can be optimized before conditioning begins. Low cell counts found now can be addressed before collection day.
- Creates informed treatment planningCardiac and organ function baseline informs exactly how the team manages each subsequent phase of treatment.
Limitations
- Adds weeks to an already anxious waitThe workup phase is experienced as real frustration. The team should be explaining what each test is looking for as it is ordered. If they are not — ask.
- Some results require re-testing at the treating centerBlood work from three months ago elsewhere doesn't reflect current status. Some tests will need repeating even if you just had them.
When to Consider This Option
Start gathering your records before your first screening appointment — treatment summaries from prior institutions, old imaging, existing genomic results. Centers with your complete prior documentation run through the workup faster. The parts that cause delays are usually the parts that require waiting for records that weren't assembled in advance.
Frequently Asked Questions
Pre-Treatment Testing Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Ready to Start the Gene Therapy Evaluation Process?
The workup begins with your existing records. Upload your prior treatment summaries, imaging, and genomic profiling results and our specialist team will assess where you are in the eligibility process.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.